Vetr Inc. announced Mallinckrodt PLC (NYSE:MNK), bumping up its stock price target to $83.20 today
- Updated: September 16, 2016
Boasting a price of $81.48, Mallinckrodt PLC (NYSE:MNK) traded 0.20% lower on the day. With the last close up 16.22% relative to the 200-day moving average, compared with the S&P 500 which has fallen -0.01% over the date range. Mallinckrodt PLC has been tracking to a 50-day moving average of $76.82 and two hundred day moving average of $65.50. 1,760,528 shares of the stock traded hands, up from ann average trading volume of 1,660,590
Vetr Inc. bumped the price target of Mallinckrodt PLC (NYSE:MNK) to $83, stating a possible upside of 0.02%,
Previously on 8/12/2016, Stifel released a statement about Mallinckrodt PLC(NYSE:MNK) bumped the target price from $0.00 to $95.00 that suggested an upside of 0.20%.
Recent Performance Graph:
A total of 15 firms have released a ratings update on the stock. Six analysts rate the stock a strong buy, seven analysts rate the stock a buy, two analyts rate the stock a hold, 0 rate the company to underperform, and finally 0 analystsrate the stock as sell with a one year target price of $88.67
Mallinckrodt PLC has a 52 week low of $50.90 and a 52 week high of $85.83 with a price-earnings ratio of 14. MNK’s total market value is currently $0.0.
About Mallinckrodt PLC (NYSE:MNK)
Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging. Its Specialty Brands segment produces and markets branded pharmaceutical and biopharmaceutical products for autoimmune and rare diseases; immunotherapy and neonatal respiratory critical care therapies, and central nervous system drugs. Its Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic controlled substances, and acetaminophen and other active ingredients. Its Nuclear Imaging segment manufactures and markets radiopharmaceuticals (nuclear medicine).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.